Archived story2 articles · 2 publishers
FDA delays mifepristone safety review until March
- Published
- Updated
- Reports
- 2 from 2 publishers
The FDA disclosed in a court filing that its safety review of the abortion pill mifepristone will not be published until March and that it will impose no new restrictions before then. The timeline drew criticism from abortion rights opponents who had hoped to see the drug's use curtailed.
AI summary · Original reporting is linked alongside
How the outlets frame it
2 outlets, each read from its own headline and openingTap a logo to see the outlet, the headline it was read from, and where it sits on every measure.
Does the report cast the development as bad news or good news?
CBS News reads as leans negative, The Hill as neutral.
Does the report play the story up to grab attention?
Both read as measured.
Do the words judge rather than describe?
The Hill reads as neutral wording, CBS News as some charged words.
Does the report give room to one side only?
The Hill reads as straight, CBS News as one-sided.
All 2 outlets and the headlines they were read from
CBS News
FDA says its abortion pill safety review will continue into next yearFraming: Leans negative · Sensationalism: Measured · Loaded language: Some charged words · Slant: One-sided
The Hill
FDA: Mifepristone review won’t be done until MarchFraming: Neutral · Sensationalism: Measured · Loaded language: Neutral wording · Slant: Straight
Each outlet is read blind: a classifier sees its headline and opening next to the story's own headline, without the outlet's name, and scores how the report presents the story. A logo sits at the classifier's average reading, so it can fall between two levels. These readings compare coverage of this story only; they are not ratings of the outlets.
The story as a whole
Read from all the reports togetherDeveloping and expected to update
No time pressure
Disputed but objectors are unnamed
Attributed to named officials or documents
No violence reported
Other signals
8 found · 13 not present- Article typeNews report
- Policy areaReproductive policy
- Government levelFederal
- Where it happensUnited States national
- What a reader getsNew facts
- ToneNeutral and factual
- Main political actorA government agency
- Public healthA treatment or drug
- Topicnot present
- Civil liberties questionnot present
- Market relevancenot present
- Which marketunclear
- Market horizonnot present
- Who is economically affectednot present
- Corporate dimensionnot present
- Conflict dimensionnot present
- Conflict direction reportednot present
- Humanitarian impactnot present
- Public safetynot present
- Scientific evidencenot present
- Legal risk in the reportingnot present
The 10 stories everyone is covering, in your inbox at 7 am your time.
grouped.news is free, independent and has no paywall. If it saves you time, chip in.Buy us a coffee ↗